Your payment is in progress...
  +1 (704) 266-3234

Male Hypogonadism Global Clinical Trials Review, H2, 2016

Published on: Dec 2016 | From USD $2500 | Published By: GLOBAL DATA | Number Of Pages: 220

Male Hypogonadism Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Male Hypogonadism Global Clinical Trials Review, H2, 2016" provides an overview of Male Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Male Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Male Hypogonadism to Male Health Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Male Hypogonadism to Male Health Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Male Hypogonadism Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Male Hypogonadism 30
Dec 05, 2016: Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate 30
Nov 30, 2016: Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel 30
Nov 21, 2016: Diurnal Group: First patient dosed in testosterone replacement therapy for hypogonadism 31
Nov 02, 2016: Antares Pharma Announces Presentations at the Sexual Medicine Society Scientific Annual Meeting 31
Oct 28, 2016: Antares Pharma Announces Multiple Presentations at the Sexual Medicine Society Scientific Annual Meeting 33
Oct 05, 2016: Acerus Announces Canadian Commercial Launch of NATESTO 33
Sep 26, 2016: Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy 34
Clinical Trial Profile Snapshots 35
Appendix 217
Abbreviations 217
Definitions 217
Research Methodology 218
Secondary Research 218
About GlobalData 219
Contact Us 219
Disclaimer 219
Source 220

List of Figures
Male Hypogonadism Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Male Hypogonadism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Male Hypogonadism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Male Hypogonadism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Male Hypogonadism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Male Hypogonadism Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Male Hypogonadism Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Male Hypogonadism Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Male Hypogonadism to Male Health Clinical Trials, G7 Countries (%), 2016* 14
Male Hypogonadism Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Male Hypogonadism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Male Hypogonadism to Male Health Clinical Trials, E7 Countries (%), 2016* 17
Male Hypogonadism Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Male Hypogonadism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Male Hypogonadism Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Male Hypogonadism Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Male Hypogonadism Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Male Hypogonadism Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Male Hypogonadism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Male Hypogonadism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Male Hypogonadism Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Male Hypogonadism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Male Hypogonadism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 218

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2500
USD $5000
USD $7500
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.